Author | Matthew D. Galsky, MD | OncLive

Author | Matthew D. Galsky, MD

Articles

Dr. Galsky on Sequencing Questions in Urothelial Cancer

June 23, 2020

Video

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Dr. Galsky on the HCRN GU14-182 Study Results in Urothelial Cancer

August 06, 2019

Video

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 07, 2017

Article

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 04, 2015

Article

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

x